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Abstract
The immediate objective of our
research aims to create stable cell lines
to generate sufficient amounts of viral
E1. The pMSG vector was chosen for
its ability to amplify gene expression
by way of hormonal or chemical
induction, and for its ability to be
selected under ampicillin medium by
way of the Amp gene. pMSG was
ligated with E1 insert in two fashions,
blunt or modified ends. Inserts were
created by way of digesting them with
BamH1. The inserts were blunted and
ligated with a blunt ended pMSG, or
blunted, modified, digested with Sal 1
and then ligated with Sal 1 digested
pMSG. Recombinants were
transformed in E. coli cells, plated in
ampicillin medium, and analyzed by
way of electrophoresis. When
analyzing the blunt ended technique,
bacterial contamination was depicted
by faint bands in the upper region of
the gel. Products could not be
analyzed from the Sal 1 ligated
technique, due to complications and
errors in plating. reating sufficient
amounts of E1 protein by way of using
blunt and modified ends to form
recombinants proved difficult,
yielding no desired products.
Therefore, there must be further
research to find a protocol to generate
sufficient amounts of E1 from
mammalian cell lines.

Introduction
Cervical cancer is one of the
leading causes of cancer-deaths in
women worldwide (1). From the 150
genomic strains of the human
papillomavirus (HPV), two strains, HPV
16 and 18, are known to cause cervical
cancer, yet most commonly, other
strands of the papillomavirus are known
to produce benign hyperproliferative
lesions (warts) in epithelial cells they
infect (1, 2). The papillomavirus encodes
a protein called E1, which is essentially
responsible for initiating the replication
of viral DNA (2, 3). E1 is highly
controlled by the host cell. Hopefully,
understanding the mechanism by which
the host cell initiates viral DNA
replication, will give insight to the
mechanism by which the host cell
initiates its own DNA replication, as
well as, shed light on ways to avert
cervical cancer caused by HPV (4).
Thus, the objective of this research is to
map and compare phosphorylation sites
on the E1 protein from HPV and the
bovine papillomavirus (BPV). However,
due to the difficulty to attain large
amounts of E1, the immediate objective
of this research is to create stable cell
lines to generate sufficient amounts of
viral E1 protein.
HPV and BPV Genome
The BPV and HPV genome are
fairly similar and differ only slightly,
therefore, we are able to utilize both
forms of the papillomavirus in forming
recombinants. The virus is enclosed
within a protein capsid and has eight
genes (5). It exists as a closed double
stranded 8kbp and is usually found in
cells as a supercoiled closed circular
molecule or episome (1, 2, 5, 6). It has
eight viral open reading frames (ORFs)
and has three regions (2, 5): early region,

nonstructural viral replication proteins
E1-E7; late region, two structural
proteins L1 and L2 that create the
capsid; the long control region (LCR),
for regulation of viral replication (5).
The E1 protein from both BPV and HPV
is the most highly conserved of the
papillomavirus genes (3).
Viral Life Cycle
It is the virus’ peculiar life cycle
that makes it indispensable to this
research. The virus undergoes stages
during its life cycle: entry, viral

replication, productive viral infection,
and host containment, which is depicted
in Figure 1 (5). Upon infection, the virus
sheds its protein coat, injects its viral
material in the cytoplasm of the host
cell, and then travels to the nucleus,
where it resides as an episome (5). A
primary target for infection is the
stratum germinativum also called the
basal layer (5, 6). The productive stage
is marked by the translation of the late
genes, which occurs in the outer layers
(5).

Figure 1. Infection of HPV and location of viral assembly within the layers of the epidermis (5).

As infected basal cells undergo
mitosis, daughter cells begin to carry
transcriptionally active episomal HPV
DNA. Migration of daughter cells
initiate a differentiation pathway (2, 7,
8). Within the granulosum and the
corneum, terminal differentiation occurs
(8). Then viral DNA is amplified, which
is followed by the production of proteins
produced by the L1 region that envelope
each episomal DNA with a protein
capsid (3, 7, 8). In summary,

differentiation signals a change in the
amount of viral DNA produced,
synthesis of virus structural proteins, and
assembly of progeny virions (2, 3, 8).
A depiction of the link between
the life cycle of HPV to cellular
differentiation can be seen in Figure 2
(8). The diagram comparing the location
of where DNA synthesis and late gene
expression take place, as well as which
viral particles are produced, aid in
visually representing how and where the

reproductive stage switches to the
productive stage.

Figure 2. Schematic representation of the abnormal differentiation induced by HPV Infection. Viral
replication occurs all throughout the layers, whereas late gene expression or the production of virions
is found only in the stratum granulosum (8).

During the reproductive stage,
roughly 50 to 200 copies of viral DNA
are present and no structural proteins are
produced (2, 8). However, when
differentiation occurs, there is a change
in the transcription program of the cell,
causing the synthesis of thousands of
viral DNA molecules (2, 5, 7, 8). The
exact mechanism by how this occurs is
still unknown. However, we can
speculate that there is interplay of host,
viral, and environmental factors that may
induce these changes (2, 3). Ultimately,
we speculate that the life cycle of the
human papillomavirus is differentially
induced (2, 4, 7). Thus, we focus on the
E1 protein of papillomavirus protein.
E1 Function
E1 is a helicase that triggers and
induces viral DNA synthesis, and is
known to be upregulated during
differentiation (2, 3). E1 is regulated by
way of phosphorylation and plays a role
in ATPase, helicase, and viral replication

(2, 3, 8, 9). Although the entire protein
structure is unknown, we know that E1
protein has two domains (2, 10). The
first domain binds to the origin and the
other domain acts as a helicase. E1’s
DNA binding domain (E1 DBD) binds
adjacent to E2 while it binds to its DBD.
The binding of both proteins to DNA
creates a sharp bend that will allow E1’s
helicase domain (E1HD) to interact with
E2’s transcriptional activation domain
(E2 AD). E2 leaves the complex, and E1
is now recruited to the complex. The
helicases can now move in both
directions to unwind DNA, thus
resulting in replication (10). Figure 3
depicts the proposed mechanism.

Figure 3. E1 interacts with both the DNA
biding domain of the virus as well as the E2.
E2 is kicked off while additional E1 proteins
complex to form the E1 helicases (10).

Phosphorylation
Phosphorylation plays a role in
regulating the function of E1. It is
known that kinases, such as Cdks, PKC,
and CK2, phosphorylate various
positions in the amino-terminal third of
E1 (2, 3, 8, 9). E1 is necessary for
regulating the replication of viral DNA
both positively and negatively (3).
Obtaining sufficient amounts of
E1 to analyze is difficult. Currently, E1
is being successfully produced by way of
insect cells. One drawback to using
insect cells, is that insect kinases may
target different sights. This again
emphasizes the need to compare and
map E1 protein from different sources.
In mammalian cells, E1 is has high
turnover rate and degrades soon after it
is transcribed preventing extensive
analysis of the protein function. Being
that E1 is a helicase, the production of

large amounts of E1 may be toxic to the
cell, therefore, it is difficult to have high
expression in cells. Additionally, E1 is
transient in that when it is cloned, only a
very small amount actually expresses the
protein. Truly, there is a need to
conceive a way to produce enough E1 in
mammalian cells (2, 4). To overcome
this problem our immediate goal is to
produce stable cell lines to generate
sufficient amounts of E1 protein.
Methods and Materials
PMSG, a 7.6 kb plasmid, was
chosen as a vector for its ability to
induce expression of the E1 gene when
exposed to dexamethasone, a synthetic
glucocorticoid hormone (4, 12). We can
control expression in hopes to lessen the
effects of cellular toxicity from large
amounts of E1. Additionally, pMSG can
integrate stably into several cell lines:

mouse, hamster, and human (11).
pMSG also has the Amp gene, making it
resistant to ampicillin and enabling us to
select for recombinants in E. coli (11,
12). It also has the gpt gene which

makes the cells resistant to
mycophenolic acid (12). Resistance to
mycophenolic acid allows for the
selection of cells containing stable
recombinants (12).

Figure 4. pMSG vector containing a Sma1 and Sal 1 restriction sites. Inserts are induced by the
MMTV promoter and selection is aided by the Amp gene (obtained from Dr. M. Lentz).

We used two methods to create a
recombinant. First, recombinants were
made by ligating blunted ends, and
second, the creation of recombinants by

ligating modified ends. A depiction of
both methods can be seen in Figure 5.
Successful completion of each step will
be monitored using gel-electrophoresis.
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Figure 5. Two approaches to create a recombinant. Both inserts are digested with BamH1 and
staggered ends from Bam H1 are filled with dNTPS with the aid of a pol 1 Klenow. For the first
technique pMSG is digested with Sma 1 and ligased with the blunt ended insert. The second
technique, blunt ended inserts are modified with the addition of linkers, then digested with Sal 1.
This modified insert will then be ligased with Sal 1 digested pMSG.

Overall, inserts will be digested
with Bam H1 to form staggered ends,
which will be filled to form blunt ends
by using Klenow, portions of a Pol 1
enzyme derived from E. coli. The first
portion of the research aims to join blunt
ends created from the Klenow to the
blunt ends from a Sma 1 digest on
pMSG. The second portion of the
research adds portions of DNA called
linkers to the insert, which will then be
digested by Sal 1 and ligated to pMSG
which has also been digested with Sal 1.

SMA 1
Two sources of E1 were used:
HPV E1 and BPV E1. BPV E1 and HPV
E1 were digested with BAMH1, while
pMSG was digested with Sma1 as seen
in Table 1. pMSG was treated with
phosphatase to prevent recircularization.
Purified water was used throughout the
entire project to prevent contaminants.
Electropheresis gels were used to
determine completion of digests,
separation, and isolation. The correct
bands were identified, removed, and
isolated from gels.

H20
DNA
10X Buffer
Bam H1
Sma 1
Total

pMSG (µL)
21
5
3
--------2

HE1 (µL)
21
5
3
1
---------

30

30

BE1(µL)
21
5
3
1
---------30

Table 1. Amount of Solution Used for Digest.

E1 was isolated from the gel by
gene clean. This process removed DNA
from the gel by using glass milk (silica)
and several rounds of centrifugation in
order to isolate the viral DNA. Again,
analyzing the results from a gel
electrophoresis aids to determine the
concentration of our DNA. The ends of
Table 2: Volumes Used to Blunt Ends

DNA
dNTPs
10X buffer
Klenow

HE1 and BE1 are blunted by filling in
the staggered ends. Pol I enzyme
Klenow was used along with the
addition of dinucleotide triphosphates
(dNTPs) and added in the volume
amounts seen in Table 2. This process
was followed by another gene clean.

HE1 (µL)
24
2
3
1

BE1(µL)
24
2
3
1

Table 2. Volumes Used to Blunt Ends.

Table 3 shows the volumes used
to prepare the ligation. A negative
control is found in tube 1 because it does
not contain either BE1 or HE1.
Therefore, no E1 insert will be found
and cannot form a recombinant. Tube 2
is our positive control because kinase is
present. Kinase adds phosphates to the
ends making them able to form
recombinants. Tubes 3, 4, 5 contained
BE1 increasing in 3ul increments (3, 6,

9). Tubes 6, 7, 8 contain HE1 and also
increase in amounts of HE1 (3, 6, 9).
Total volume of each tube equals 30 uL.
Each tube was vortexed and then slightly
shaken to make sure all solution was at
the bottom of the tube and placed to
incubate at 37C for greater than 1 hour.
.5 uL of ligase was then added again and
incubated at 16C over night in a freezer.
Ligation was again followed by
performing a gene clean.

1
(µL)

2
(µL)

3
(µL)

4
(µL)

5
(µL)

6
(µL)

7
(µL)

8
(µL)

H20

23.5

22.5

20.5

17.5

14.5

20.5

17.5

14.5

pMSG

3

3

3

3

3

3

3

3

BE1

------

------

3

6

9

-----

-----

----

HE1

-----

-----

-----

---

----

3

6

9

10X
Buffer

3

3

3

3

3

3

3

3

Ligase

.5

.5

.5

.5

.5

.5

.5

.5

Kinase

-----

1

-------

-----

------

-----

-----

-----

Total
Volume

30

30

30

30

30

30

30

30

Table 3. Ligation Volumes.

Ligation was followed by
transformation and plating on LB
ampicillin plates. Next, E. coli cells were
created that will uptake the circular
recombinants. The solution was then
plated on LB ampicillin plates at 37C
upside down overnight. 6 colonies from
BE1 plates and 6 from HE1 plates were
chosen. They were transferred to tubes
containing 4ml of LB amp broth. DNA
was isolated via detergent lysis and
centrifugation and was ran through a gel

H20
DNA
10X Buffer
Bam H1
Sal I
Total

pMSG (µL)
21
5
3
--------2
30

in order to determine if it contained the
desired product.
SAL 1
Procedures for the modified end
approach closely mimicked the Sma 1
approach as seen in Table 4. For further
information see the Sma 1 digest. To
blunt the inserts, 2.5 uL of 10X buffer,
1uL of 2mM dNTPs, and 1uL of Klenow
was incubated at 30C for thirty minutes,
followed by a gene clean.

HE1 (µL)
21
5
3
1
--------30

Table 4. Sal 1 Volumes for Digest.

BE1(µL)
21
5
3
1
---------30

Blunted ends are followed by the
linker-ligase treatment. DNA samples of
HE1 and BE1 were dried, and then H20
was added to make the total volume of
DNA and water equal to 14µL. Added to
this mixture was 2µL of 10X buffer, 2µL
of linker, and 1µL of Sal 1 ligase which
is left at room temp for 1-3 hours. 1µL
of ligase is again added to the solutions,
which is placed in a water bath. The
water bath is placed with the lid on
inside a freezer to slowly decrease the
temp of the bath over night.
Sal 1 is used to digest the
modified inserts. After removing the
DNA samples from the freezer, they are
heated to 65-70C for 15 minutes. A

H20
pMSG
HE1
10X Buffer
Ligase

1 (µL)
20
6
--------3
1

solution containing, 68uL of H20, 20uL
of DNA, 10uL of 10X buffer, and 2uL of
Sal 1 is created to perform a digest on
the modified inserts. After incubation at
37C for more than two hours, 1uL of Sal
1 is again added and incubated for at
least 2 more hours, which is followed by
performing a gene clean.
The ligation of Sal I inserts with
the Sal 1 digested pMSG can be seen in
Table 5. Everything remains constant
except for the volume of HE1 used.
There is a negative control seen in Tube
1 containing no HE1. Ligation was
followed by a gene clean. Ligation was
followed by transformation and plating,
which is similar to the Sma 1 process.

2 (µL)
16
6
4
3
1

3 (µL)
12
6
8
3
1

4 (µL)
8
6
12
3
1

Table 5.

Results
The following are Polaroid’s of
the gels. Figure 6 shows successful
digestion of pMSG by Sma 1. The boxed
bands are removed and isolated. Figure

7, shows successful isolation and aids in
determining the concentration of HE1
and BE1 present. Figure 8 confirms the
presence and successful blunting with
Klenow.

pMSG

HE1

BE1
pMSG

Figure 6. Digest and isolation
of pMSG by Sal 1 enzyme.
Digest of HPV and BPV by
Bam H1 enzyme. Red boxes
Represent vector and insert
to be isolated.

HE1

BE1

Figure 7. Analysis of DNA concentration
of pMSG, HE, and BE1 after isolating the
bands of DNA from the previous gel.

HE1

BE1

Figure 8. The two lower bands
labeled HE1 and BE
are the inserts and display
the successful filling in of the
staggered ends with Klenow.

Figure 9. Analysis of DNA from Colonies Grown in Ampicillin to determine desired product. Lower
bands represent RNA and faint upper bands represent bacterial chromosomal contamination.

pMSG

Firgure 10. Successful Sal 1
digest of pMSG.

Figure 10, depicts successful
digest of pMSG by Sal 1. Figure 11
depicts the successful isolation of bands
from digests in Figure 10. Unfortunately,
no Polaroid’s were taken after the

pMSG

BE1

HE1

Figure 11. Analysis of DNA concentration
of pMSG, HE1, and BE1 after isolating
the bands from the previous gel.

transformation, because no growth was
seen on the plates.

Discussion
Although scientists have yet to
understand the exact mechanism of how
cellular DNA replication is induced, much
insight can be gained by understanding how
cellular mechanisms affect viral E1 protein
to initiate viral replication. Difficulties still
abound in generating sufficient amounts of
viral E1 protein from mammalian cells to
analyze, which can be seen in our research.
Forming recombinants to introduce into
mammalian cells posed a difficult task, due
to the lack of success in creating
recombinants. It is difficult to determine
which method is more efficient in producing
recombinants to generate stable mammalian
cell lines. Although growth was seen from
the blunt ended treatment, the desired
product was not found in Figure 9.
Alternatively, because no growth was found
from the modified treatment, we are not able
to analyze the desired product as seen in
Table 6. As seen in Table 6, it is expected
that the staggered ends of Sal 1 should be
more able to produce recombinants because
the ends created by Sal 1 exposes hydrogen
that can readily bond with single and
complimentary stranded Sal 1 digested
pMSG (13). The inability to produce
recombinants could stem from human error
or old enzymes and DNA. Further research

should aim at discovering where the errors
occur to best gain recombinants. Because
neither approach resulted in stable
recombinants, further research must be done
to create stable recombinants to incorporate
into mammalian lines. If stable
recombinants were created it would result in
a vector that could be placed into a
mammalian cell lines to produce E1. Large
amounts of E1 would then be readily
available for extensive analysis. Scientists
would then be able to map and compare
phosphorylation sites from both sources of
HPV and BPV to determine similarities and
differences.

Sma 1

Sal 1

Modified

Blunt
E1 ends
5’ccc ggg3 ’
3’ggg ccc5 ’

5'G TCGAC-3‘
3'-CAGCT G-5'

Growth

YES

NO

Desired
Product

NO

No gel
--------

Table 6. Summary of results showing which enzyme was used, the ends that results from each
enzyme, the type of insert used to make a recombinant, and if the recombinant resulted in growth in
an ampicillin medium, and whether the DNA recovered from the colonies resulted in the desired
product.
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